Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, Merck & Co., Inc. and Merus N.V. present a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Merck, a giant in the industry, consistently reported SG&A expenses in the range of $9.6 billion to $11.6 billion annually. In contrast, Merus, a smaller player, saw its expenses grow from under $1 million in 2015 to nearly $60 million by 2023.

This stark difference highlights the scale and operational strategies of these companies. While Merck's expenses reflect its expansive global operations, Merus's growth in SG&A expenses, increasing by over 7000% in less than a decade, signals its aggressive expansion and investment in market presence. This comparison not only underscores the diverse strategies within the pharmaceutical sector but also offers insights into how companies allocate resources to maintain competitive edges.